Prion Protein as a Toxic Acceptor of Amyloid-β Oligomers
- PMID: 29331212
- DOI: 10.1016/j.biopsych.2017.11.020
Prion Protein as a Toxic Acceptor of Amyloid-β Oligomers
Abstract
The initial report that cellular prion protein (PrPC) mediates toxicity of amyloid-β species linked to Alzheimer's disease was initially treated with scepticism, but growing evidence supports this claim. That there is a high-affinity interaction is now clear, and its molecular basis is being unraveled, while recent studies have identified possible downstream toxic mechanisms. Determination of the clinical significance of such interactions between PrPC and disease-associated amyloid-β species will require experimental medicine studies in humans. Trials of compounds that inhibit PrP-dependent amyloid-β toxicity are commencing in humans, and although it is clear that only a fraction of Alzheimer's disease toxicity could be governed by PrPC, a partial, but still therapeutically useful, role in human disease may soon be testable.
Keywords: Alzheimer’s disease; Amyloid; Neurodegeneration; Oligomers; Prion; Therapeutics.
Copyright © 2017. Published by Elsevier Inc.
Comment in
-
Reply to: Intrinsic Toxicity of Antibodies to the Globular Domain of the Prion Protein.Biol Psychiatry. 2018 Oct 1;84(7):e53-e54. doi: 10.1016/j.biopsych.2018.04.002. Epub 2018 Apr 12. Biol Psychiatry. 2018. PMID: 29752071 No abstract available.
-
Intrinsic Toxicity of Antibodies to the Globular Domain of the Prion Protein.Biol Psychiatry. 2018 Oct 1;84(7):e51-e52. doi: 10.1016/j.biopsych.2018.01.028. Epub 2018 Apr 12. Biol Psychiatry. 2018. PMID: 29752074 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
